Enliven Therapeutics (ELVN) Cash & Equivalents (2019 - 2026)

Enliven Therapeutics (ELVN) has 8 years of Cash & Equivalents data on file, last reported at $132.2 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents rose 29.97% year-over-year to $132.2 million; the trailing twelve-month figure through Mar 2026 stood at $132.2 million (up 29.97% YoY), and the FY2025 full-year result was $98.9 million, down 20.32% from the prior year.
• Cash & Equivalents grew to $132.2 million in Q1 2026, from $98.9 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $292.1 million in Q1 2023 to a low of $73.8 million in Q3 2023.
• A 5-year average of $115.9 million and a median of $100.6 million in 2024 frame the typical range for Cash & Equivalents.
• Across the five-year window, Cash & Equivalents surged 192.46% in 2023 and sank 48.93% in 2024, its largest moves.
• Tracing ELVN's Cash & Equivalents over 5 years: stood at $75.5 million in 2022, then surged by 32.57% to $100.1 million in 2023, then climbed by 23.94% to $124.1 million in 2024, then dropped by 20.32% to $98.9 million in 2025, then jumped by 33.66% to $132.2 million in 2026.
• Business Quant data shows ELVN's Cash & Equivalents at $132.2 million in Q1 2026, $98.9 million in Q4 2025, and $101.7 million in Q3 2025.